Blog Big Molecule Watch March 22, 2017

Celltrion Files Two Additional Petitions for IPR on Genentech’s Trastuzumab Patents

Celltrion has filed petitions for inter partes review of two patents related to Genentech’s trastuzumab:  IPR2017-01121, challenging U.S. Patent 7,846,441, and IPR2017-01122, challenging U.S. Patent 7,892,549.  According to the petitions, these two patents claim methods of treating patients with a sub-type of breast cancer with trastuzumab.  These filings follow Celltrion’s earlier filing on a different trastuzumab patent, as we previously reported.

Trastuzumab is marketed by Genentech under the trade-name Herceptin®.

These petitions and other significant PTAB filings on biologic patents are collected on our IPR tracker page.